www.ecoanimalhealthgroupplc.com
ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
ECO Animal Health Group’s Chinese Aivlosin factory gets US FDA approval
ECO Animal Health Group (LON:EAH) told investors that its Chinese manufacturing facility has been approved by the US Federal Drug Administration (FDA), following a successful Good Manufacturing Practice (GMP) inspection.
The facility manufactures the Aivlosin active pharmaceutical ingredient.
The company said the approval marks a very important milestone in the development and registration programme for Aivlosin in the USA.
The facility has already been approved by EU and Japanese regulatory authorities.
ECO Animal Health Group develops, registers and markets pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel macrolide antibiotic, Aivlosin, as well as a range of generic therapeutic products.
Aivlosin targets a wide range of diseases spanning from enzootic pneumonia to swine dysentery. The drug has been approved for use in pigs and poultry in Europe, South Africa, Japan, Asia and South America with ECO expecting it to receive approvals soon for use in pigs in the United States.
The group’s other products include Chlortet, which is aimed at controlling E.coli infections, and performance promoters such as Flaveco, designed to improve efficiency and growth in pigs.
ECO also announced that its full-year results, for the year ended 31 March 2010, will be published on 10 August 2010.
















